Aromatase inhibitors, which include letrozole, exemestane and anastrozle, are applied to clinic for postmenopausal women with oestrogen receptor (ER+) and/or progesterone receptor (PR+) early breast cancer as well [8, 9]. Here, PGR is linked to breast carcinoma.